Should I Buy INMD? INMD 2026 Analysis

Should You Buy Inmode Ltd (INMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

16.020

1 Day change

5.95%

52 Week Range

19.780

Analysis Updated At

2026/01/29

InMode Ltd (INMD) is a good buy for a beginner investor with a long-term investment horizon and $50,000-$100,000 available for investment. The recent acquisition proposal by Steel Partners at a 29% premium, coupled with technical indicators showing bullish momentum, makes this an attractive opportunity despite recent financial underperformance. The stock's current price of $15.81 is below the proposed acquisition price of $18, offering potential upside.

Technical Analysis

The technical indicators are showing bullish momentum. The MACD histogram is positive and expanding, the RSI is at 77.936 (neutral zone), and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot point of 14.798, with resistance levels at 15.701 and 16.259. This suggests a positive price trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market, with more interest and volume in calls compared to puts.

Technical Summary

Sell

Buy

Positive Catalysts

Steel Partners' acquisition proposal at $18 per share, representing a 29% premium to the current price.
Bullish technical indicators and positive sentiment in the options market.
Potential investor interest in the Med-Tech sector due to AI-driven advancements and M&A activity.

Neutral/Negative Catalysts

Poor financial performance in Q3 2025, with revenue, net income, and EPS all declining significantly year-over-year.
Analyst ratings are neutral, with price targets recently lowered (Canaccord to $15 and UBS to $16).
No recent significant trading activity from hedge funds, insiders, or Congress.

Financial Performance

In Q3 2025, InMode reported a revenue decline of -28.46% YoY to $93.165M, net income dropped -57.12% YoY to $21.863M, and EPS fell -47.69% YoY to $0.34. Gross margin also decreased to 77.61%, down -4.81% YoY. The financials indicate significant challenges in growth and profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have a neutral stance on INMD. Canaccord recently lowered its price target to $15 from $16, citing optimism in the Med-Tech sector but highlighting depressed valuations. UBS also reduced its price target slightly to $16 from $16.25, maintaining a Neutral rating.

5 Analyst Rating

Wall Street analysts forecast INMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMD is 17.33 USD with a low forecast of 15 USD and a high forecast of 21 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

0 Sell

Hold

Current: 15.120

Low

Averages

17.33

High

Current: 15.120

Low

Averages

17.33

High

Canaccord

Hold

downgrade

$16 -> $15

AI Analysis

2025-12-17

Reason

Canaccord

Price Target

$16 -> $15

AI Analysis

2025-12-17

downgrade

Hold

Reason

Canaccord lowered the firm's price target on InMode to $15 from $16 and keeps a Hold rating on the shares. The firm said they are bullish on the Med-Tech sector heading into 2026 as they expect investor interest given smid-cap valuations continue to remain depressed, while M&A has picked up and the IPO market has opened in some respects. They also highlight how AI is changing our space, enabling improved patient outcomes, increased procedure volumes, more efficiency at the corporate level, and improved surgical accuracy/reproducibility, which they believe could drive some of the greatest changes in healthcare at a time when the system is capacity constrained and in desperate need of solutions.

UBS

Neutral

downgrade

$16

2025-11-06

Reason

UBS

Price Target

$16

2025-11-06

downgrade

Neutral

Reason

UBS lowered the firm's price target on InMode to $16 from $16.25 and keeps a Neutral rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INMD

Unlock Now

INMD Should I Buy

INMD Should I Buy

Should You Buy Inmode Ltd (INMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch